netFormulary Joint Medicines Formulary NHS
Airedale NHS Foundation Trust
Airedale, Wharfedale and Craven CCG
 
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
Notes:
Unless explicitly stated, any brand names included in brackets next to a drug's generic name are there solely to aid searching and identification, and should not be considered to limit use to that specific brand. 
Chapter Links...
 Details...
01.05.03  Expand sub section  Drugs affecting the immune response
Tofacitinib (Xeljanz®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Homecare
  • Tofacitinib film-coated tablets
     
    For the treatment of moderatley to severely active ulcerative colitis in line with NICE TA547.
 
Link  DSU: Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections (March 2020)
Link  DSU: Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing (May 2019)
Link  NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis (November 2018)
   
Ustekinumab injection
(Stelara®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
  • Ustekinumab injection

    For the treatment of moderately to severely active Crohn’s disease in-line with NICE TA456.

    Gastroenterology use only 
  • Link  NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment (July 2017)
    Link  TA633: Ustekinumab for treating moderately to severely active ulcerative colitis (June 2020)
       
    Vedolizumab (Entyvio®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Vedolizumab Injection

    For use in-line with NICE guidance 
  • Link  NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis (June 2015)
    Link  NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy (August 2015)
       
    01.05.03  Expand sub section  Cytokine inhibitors
    Adalimumab Subcutaneous Injection (Humira®, Amgevita®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Adalimumab Injection

      Consultant Gastroenterologist and Paediatricians only
      For use in-line with NICE guidance
     
    Golimumab Subcutaneous Injection (Simponi®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Golimumab Subcutaneous Injection

      Consultant Gastroenterologist only
      For use in-line with NICE guidance
     
    Link  NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)
       
    Infliximab infusion (Remicade®, Rensima®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Infliximab Intravenous Infusion

      Consultant Gastroenterologist and Paediatricians only
      For use in-line with NICE guidance
     
    Link  NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)
    Link  NICE TA163: Infliximab for acute exacerbations of ulcerative colitis (December 2008)
    Link  NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (May 2010)
       
     ....
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Green

    Green - Drugs suitable for generalised use in accordance with position summary. Inform primary care of need to prescribe using a TTO chart if in patient or Treatment Advice Note (TAN) if Outpatient.   

    Amber

    Amber - these drugs require specialist initiation or recommendation  

    Amber SCG

    Amber Share Care - Drugs suitable for generalist use, in accordance with position summary, normally following specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.  

    Red

    Red - Drugs for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

    Red ULM

    Red ULM - Unlicensed medicines for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

    Grey

    Grey drugs - No formal commissioning position. Check appropriate CCG /NHSE commissioning list or contact CCG/NHSE Medicines Management team for advice. Fill in individual funding request for appropriate CCG/NHSE. This will need to be signed by the Chief Pharmacist and a copy of the relevant DTC submission attached.   

    Black

    Black - Drugs not routinely commissioned so should not usually be prescribed  

    netFormulary